AzTrials
AzTrials

Accelerated Phase Chronic Myelogenous LeukemiaPhase 2NCT01789255

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

A Phase 2 study testing vorinostat, tacrolimus and cyclosporine in people with Accelerated Phase Chronic Myelogenous Leukemia and Adult Acute Myeloid Leukemia in Remission, run by National Cancer Institute (NCI) at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients with hematological malignancies. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
vorinostat, tacrolimus and cyclosporine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteUnited States
Study dates
Jun 2013to Mar 2014
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • A prospective patient for allogeneic HSCT for hematologic conditions, both malignant and non-malignant; donor can be unrelated marrow or peripheral blood cells; a patient with history of central nervous system (CNS) involvement is eligible if CNS disease is in remission at time of study consideration
  • The donor and recipient must have a human leukocyte antigen (HLA)-8/8 allelic match at the HLA-A, -B, -C, and -DRB1; high-resolution typing is required for all alleles
  • Diagnoses to be included:
  • Acute myelogenous leukemia at the following stages:
  • First remission
  • Second or subsequent remission
Show all 61Show fewer
  • Complete remission is defined as the absence of blasts in the peripheral circulation at the time of enrollment and < 5% blasts in the bone marrow
  • Chronic myelogenous leukemia at the following stages:
  • First or subsequent chronic phase:
  • Patient refused tyrosine kinase therapy or is otherwise not suited for it
  • Stable, not hematologic remission: blasts present in marrow and/or peripheral blood, but disease does not qualify as accelerated or blast phase
  • Hematologic remission: no blast cells or precursor cells in the blood or marrow
  • Partial cytogenetic remission: Philadelphia chromosome positive (Ph+) metaphases > 0% but < 35%
  • Complete cytogenetic remission: absence of Ph+ metaphases
  • Accelerated phase - any one of the following symptoms:
  • White blood cells (WBC) difficult to control (> 50 x 10^9/L despite therapy)
  • Rapid doubling of WBC (< 5 days)
  • 10% blasts in blood or marrow
  • 20% blasts and/or promyelocytes in blood or marrow
  • 20% basophils and/or eosinophils in blood
  • Anemia or thrombocytopenia unresponsive to standard treatment
  • Persistent thrombocytosis (> 1000 x 10^9/L)
  • Cytogenetic abnormalities in addition to Ph+
  • Increasing splenomegaly
  • Marrow fibrosis
  • Myelodysplastic syndromes at any of the following stages:
  • Refractory anemia
  • Refractory anemia with ringed sideroblasts
  • Refractory cytopenia with multilineage dysplasia
  • Refractory cytopenia with multilineage dysplasia and ringed sideroblasts
  • Refractory anemia with excess blasts-1 (5-10% blasts)
  • Refractory anemia with excess blasts-2 (10-20% blasts)
  • Myelodysplastic syndrome, unclassified
  • Myelodysplastic syndrome (MDS) associated with isolated del (5q)
  • Chronic myelomonocytic leukemia
  • Primary Myelofibrosis
  • Intermediate-2 risk or high risk disease
  • Patients should have extinguished standard of care options prior to being considered for this trial
  • Chronic lymphocytic leukemia
  • Complete remission: the disease is completely absent and no relapse occurred prior to the preparative regimen; requires all of the following:
  • Nodular partial remission: complete response with persistent lymphoid nodules in bone marrow
  • Partial remission: reduction of more than 50% in the disease burden regardless of the number of lines of therapy received
  • Mature B cell malignancies
  • Patients should have extinguished standard of care options prior to being considered eligible for this trial
  • First complete remission (CR1) confirmed: complete disappearance of all known disease; the term "confirmed" is defined as a laboratory and/or pathological or radiographic determination.
  • CR1 unconfirmed (CRU1): complete disappearance of all known disease with the exception of persistent scan abnormalities of unknown significance; the term "unconfirmed" is defined as scan abnormalities of unknown significance that are not biopsied or otherwise evaluated
  • Second or subsequent complete remission (CR2+) confirmed: the recipient relapsed, then achieved complete absence of disease without radiographic evidence of disease
  • CR2+ unconfirmed: the recipient has achieved a second or subsequent complete response but has persistent radiographic abnormalities of unknown significance.
  • Partial remission: reductions of >= 50% in greatest diameter of all sites of known disease and no new sites
  • Karnofsky >= 70%
  • Life expectancy of greater than 6 months
  • Total bilirubin =< 2.5 mg% (unless from Gilbert's disease or disease-related)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 3.0 X institutional upper limit of normal
  • Estimated or actual glomerular filtration rate (GFR) > 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal; GFR should be corrected for body surface area (BSA)
  • Diffusing capacity of the lung for carbon monoxide (DLCO) > 50%; DLCO should be corrected for hemoglobin
  • Forced expiratory volume in 1 second (FEV1) > 50%
  • Forced vital capacity (FVC) > 50%
  • Ejection fraction >= 50%
  • The effects of vorinostat on the developing human fetus are unknown; for this reason and because histone deacetylase inhibitor agents as well as other therapeutic agents used in this trial (e.g., tacrolimus and methotrexate) are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of vorinostat administration
  • Ability to understand and the willingness to sign a written informed consent document
  • Patients must be able to swallow capsules/tablets

Who cannot join

  • Patients who are not a candidate for an unrelated donor allogeneic HSCT based on the current institutional bone marrow transplant (BMT) program clinical practice guidelines; organ function criteria will be utilized per the current institutional BMT program clinical practice guidelines; there will be no restriction to study entry based on hematological parameters
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat
  • Patients undergoing a total body irradiation (TBI)-based conditioning regimen (TBI 1200 centigray [cGy])
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; patients still under therapy for presumed or proven infection are eligible provided there is clear evidence (radiographic findings and/or culture results) that the infection is well-controlled; patients under treatment for infection will be enrolled only after clearance from the Principal Investigator (PI)
  • Pregnant women are excluded from this study because vorinostat is a histone deacetylase inhibitor agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorinostat, breastfeeding should be discontinued if the mother is treated with vorinostat
  • Patients with evidence of human immunodeficiency virus (HIV) seropositivity and/or positive polymerase chain reaction (PCR) assay, human T-lymphotropic virus (HTLV)1/HTLV2 seropositivity; the safety of allogeneic HSCT is not yet well-established for this population
Show all 9Show fewer
  • Patients with evidence of hepatitis B or hepatitis C PCR positivity; hepatitis reactivation following myelosuppressive therapy can lead to fatal complications
  • Patients with a history of prolonged corrected QT interval (QTc) syndrome
  • Patients asking or who have had prior treatment with a drug like vorinostat (i.e., valproic acid) within the last 30 days

Trial locations and contacts

1 site in 1 country.

United States1 site

  • University of Michigan University Hospital

    Ann Arbor, Michigan, 48109

Other trials in United States

About this study

Official title: A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation

This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients with hematological malignancies. Vorinostat, tacrolimus, and methotrexate may be an effective treatment for GVHD caused by a bone marrow transplant.

Read the detailed description

PRIMARY OBJECTIVES:

  1. To assess the safety and the feasibility of the addition of vorinostat to tacrolimus and methotrexate GVHD prophylaxis.

SECONDARY OBJECTIVES:

  1. To determine day 100 grades 2-4 acute GVHD. II. To determine 1-year overall survival and relapse-free survival. III. To correlate plasma concentrations of inflammatory markers of acute GVHD. IV. To correlate protein acetylation in peripheral blood mononuclear cells before and after administration of vorinostat.

OUTLINE:

Patients receive vorinostat orally (PO) twice daily (BID) on days -10 to 100. Beginning on day -3, patients receive tacrolimus intravenously (IV) continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV once daily (QD) on days 1, 3, 6, and 11.

After completion of study treatment, patients are followed up periodically for 1 year.

Being tested
vorinostat, tacrolimus, cyclosporine, methotrexate, laboratory biomarker analysis
Medical subject headings
Leukemia, Myeloid, Accelerated Phase, Congenital Abnormalities, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Chronic-Phase, Graft vs Host Disease, Intraocular Lymphoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • vorinostatDrug

    Also called L-001079038, SAHA, suberoylanilide hydroxamic acid, Zolinza

    Given PO

  • tacrolimusDrug

    Also called FK 506, Prograf

    Given IV or PO

  • cyclosporineDrug

    Also called ciclosporin, cyclosporin, cyclosporin A, CYSP

    Given IV or PO

  • methotrexateDrug

    Also called amethopterin, Folex, methylaminopterin, Mexate

    Given IV

  • laboratory biomarker analysisOther

    Correlative studies

  • pharmacological studyOther

    Also called pharmacological studies

    Correlative studies

Study groups in NCT01789255
Study groupRoleWhat they receive
Supportive care (vorinostat, tacrolimus, methotrexate)ExperimentalPatients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.
Receives: Drug: vorinostat; Drug: tacrolimus; Drug: cyclosporine; Drug: methotrexate; Other: laboratory biomarker analysis; Other: pharmacological study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100

    The incidence of grade 2-4 acute GVHD (Graft Versus Host Disease) by day 100

    Grade 2 GVHD: Maculopapular rash covering 25-50% of BSA (Body Surface Area), bilirubin between 3.1-6 mg/dl, and/ or adult stool output between 1000-1500 ml/day (child between 20-30 ml/kg/day).

    Grade 3 GVHD: Maculopapular rash covering >50% of BSA, bilirubin between 6.1-15 mg/dl, and/ or adult stool output >1500 ml/day (child >30 ml/kg/day).

    Grade 4 GVHD: Generalized erythroderma plus bullous formation and desquamation >5% BSA, bilirubin >15 mg/dl, and/ or severe abdominal pain with or without ileus, or grossly bloody stool.

    Measured: Day 100

Secondary outcomes (6)

  1. Mean Percent of Planned Dose Administered

    The addition of vorinostat to tacrolimus and methotrexate for GVHD prophylaxis will be considered feasible if 60% or more of the planned doses are administered.

    Measured: Up to day 30

  2. The Percentage of Patients Alive Without GVHD or Use of Steroids

    The percentage of patients alive without GVHD or use of steroids at 1 year.

    Measured: Up to 1 year

  3. The Percentage of Patients Alive at 1 Year

    The percentage of patients alive at 1 year

    Measured: Up to 1 year

  4. The Percentage of Patients With Relapse at 1 Year

    Measured: Up to 1 year

  5. Median Ac-H3 Levels in Patients Treated With Vorinostat and Patients Not Treated With Vorinostat

    Median Ac-H3 levels ( depicted as a ratio of ac-H2 optical density (OD) and beta actin OD) were compared in patients treated with Vorinostat to patients not treated with Vorinostat. Optical Density is a dimensionless unit.

    Measured: Up to day 100

  6. Median Plasma Concentration of IL-6 in Patients Treated With Vorinostat and Patients Not Treated With Vorinostat

    Median plasma concentration of IL-6 (Interleukin-6 cytokine) was compared in patients treated with Vorinostat to those not treated with Vorinostat.

    Measured: Up to day 100

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Feb 2013 (estimated)
  2. Study startJun 2013
  3. Primary completionMar 2014
  4. Study completionMar 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01789255
Sponsor's protocol ID
NCI-2013-00355
Other IDs
NCI-2013-00355, HUM00070080, UMCC 2012.047, 9330, P30CA046592
Status last verified
Jun 2018
First submitted
7 Feb 2013
Last updated
24 Jul 2018
Data monitoring committee
Yes

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in